A	B	C	D	E	F	G	H	I	J
1	Main
2		Brand	Generic	Indication	MOA	Approved	Economics
3		Aricept	donepezil				4523, PFE
4			rivastigmine
5			memantine
6		Aduhelm, fka BIIB037	aducanumab		polymeric abeta ab		BIIB/4523/Neurimmune		no	N-terminal
7			galantamine
8		Brand	Generic	Indication	MOA	Phase	Economics	Last Trial Date	Monomer?	Epitope
9		LY3002813	donanemab		N3pG abeta ab	III ongoing	LLY
10		BAN2401	lecanemab	CDR=0.5-1.0, MMSE>=22	amyloid beta antibody	III completed	BIIB, 4523, BioArctic	3/25/2019	no
11		AAB-001	bapineuzumab		N-terminal abeta ab	III completed	ELN, PFE/WYE, JNJ	12/17/2007	yes	N-terminal
12		LY2062430	solanezumab		soluble abeta ab		LLY		yes	16-26
13		RG7412, MABT5102A	crenezumab		abeta ab		ROG			13-24
14		RO4909832	gantenerumab		abeta ab		ROG			3-11, 18-27
15		SAR228810			polymer abeta ab		SNY
16			ponezumab				Pfizer (Rinat)			30-40
17		LY3372993	remternetug		N3pG abeta ab?		LLY
18		LY3372689			O-GlcNAcase inhibitor		LLY
19		LY3303560	zagotenemab		tau mab		LLY
20		LY3154207	mevidalen		D1 pam		LLY
21		RVT-001	intepirdine
22		Dimebon					MDVN
23			azeliragon
24		Lu AE58054	idalopirdine
25		IGIV
26		CNP520	umibecestat		BACE1 inhibitor		NVS, AMGN
27		LY3202626			BACE inhibitor		LLY
28		LY3314814	lanabecestat		BACE inhibitor		LLY
29		E2609	elenbecestat		BACE inhibitor		4523 JP
30			atabecestat		BACE inhibitor		JNJ
31		MK-8931	verubecestat		BACE1 inhibitor		MRK
32		LY405139	semagacestat		gamma secretase		LLY
33		ANAVEX2-73
34			simufilam
35		UCB0107	bepranemab
36			semorinemab
37		BIIB080
38		E2814
39		IONIS-MAPTRx
40		RO7126209
41		JNJ-63733657
42		JNJ-54861911			Tau	II
43		ABBV-8E12
44		ABBV-916
45		AL002
46		ACI-35.030
47		JACI-35.054
48		ACI-24.060
49		BI 425809
50		BI 409306
51		CAD106